ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 167,50
-0,26%
Dow Jones
40 003,59
0,34%
DAX
18 704,42
-0,11%
Brent Oil
83,655
-0,13%
Bitcoin
66 225,17
-1,07%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Aridis Pharmaceuticals Inc (ARDS)

  7. Aridis Pharmaceuticals Inc (ARDS) Actualités

ARDS

Aridis Pharmaceuticals (ARDS)

Aridis Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ARDS
DateHeureSourceTitreSymboleSociété
14/02/202402h02Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ARDSAridis Pharmaceuticals Inc
16/01/202412h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARDSAridis Pharmaceuticals Inc
15/12/202322h15GlobeNewswire Inc.Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024NASDAQ:ARDSAridis Pharmaceuticals Inc
03/11/202321h15GlobeNewswire Inc.Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business UpdateNASDAQ:ARDSAridis Pharmaceuticals Inc
03/11/202311h15Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ARDSAridis Pharmaceuticals Inc
14/09/202303h47Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ARDSAridis Pharmaceuticals Inc
04/08/202322h05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ARDSAridis Pharmaceuticals Inc
02/08/202314h17GlobeNewswire Inc.Aridis Pharmaceuticals Announces $2 Million OfferingNASDAQ:ARDSAridis Pharmaceuticals Inc
02/08/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ARDSAridis Pharmaceuticals Inc
21/07/202312h49Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:ARDSAridis Pharmaceuticals Inc
17/07/202322h05GlobeNewswire Inc.Aridis Receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301NASDAQ:ARDSAridis Pharmaceuticals Inc
12/07/202314h00GlobeNewswire Inc.Aridis’ AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA’s Qualified Infectious Diseases Product (QIDP) DesignationNASDAQ:ARDSAridis Pharmaceuticals Inc
23/06/202312h01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ARDSAridis Pharmaceuticals Inc
20/06/202314h00GlobeNewswire Inc.Aridis Pharmaceuticals' AR-301 Eligible for Consideration under FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)NASDAQ:ARDSAridis Pharmaceuticals Inc
15/06/202323h16Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ARDSAridis Pharmaceuticals Inc
09/06/202312h13Edgar (US Regulatory)Securities Registration Statement (s-1/a)NASDAQ:ARDSAridis Pharmaceuticals Inc
08/06/202322h05GlobeNewswire Inc.Aridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business UpdateNASDAQ:ARDSAridis Pharmaceuticals Inc
31/05/202314h00GlobeNewswire Inc.Aridis Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study DesignNASDAQ:ARDSAridis Pharmaceuticals Inc
25/05/202322h05GlobeNewswire Inc.Aridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-QNASDAQ:ARDSAridis Pharmaceuticals Inc
26/04/202318h15GlobeNewswire Inc.Aridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-KNASDAQ:ARDSAridis Pharmaceuticals Inc
01/04/202301h00GlobeNewswire Inc.Aridis Provides Corporate UpdateNASDAQ:ARDSAridis Pharmaceuticals Inc
20/03/202321h36Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:ARDSAridis Pharmaceuticals Inc
14/03/202314h45GlobeNewswire Inc.Aridis Pharmaceuticals Announces $2.28 Million Registered Direct Offering of Common StockNASDAQ:ARDSAridis Pharmaceuticals Inc
13/03/202313h00GlobeNewswire Inc.Aridis Meets Primary and Secondary Endpoints in Phase 2a Study of AR-501 in Cystic Fibrosis PatientsNASDAQ:ARDSAridis Pharmaceuticals Inc
10/02/202316h26Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ARDSAridis Pharmaceuticals Inc
25/01/202322h05GlobeNewswire Inc.Aridis Reports Top-Line Results of the Phase 3 Double-Blinded, Superiority Trial of AR-301 For the Treatment of Staphylococcus aureus Ventilator Associated Pneumonia (VAP)NASDAQ:ARDSAridis Pharmaceuticals Inc
17/01/202322h30GlobeNewswire Inc.New Approaches to Treating Infections in Cystic Fibrosis Patients - AR 501 Phase 2 Trial UpdateNASDAQ:ARDSAridis Pharmaceuticals Inc
28/12/202214h30GlobeNewswire Inc.Aridis Pharmaceuticals to Discuss Topline Data from Phase 3 Study of AR-301 During Corporate Update Call on January 25NASDAQ:ARDSAridis Pharmaceuticals Inc
15/12/202222h34Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:ARDSAridis Pharmaceuticals Inc
12/12/202218h25TipRanksAridis Pharmaceuticals (ARDS) Gets a Buy from H.C. WainwrightNASDAQ:ARDSAridis Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ARDS

Dernières Valeurs Consultées

LSE
72DE
Santan. Perp. S
LSE
77BR
Investec Bnk 28
NYSE
AGTI
Agiliti
TG
YW5
Giant Mining
NASDAQ
AEMEQX
Acadian Emerging Markets...
COIN
BICASBTC
BitherCash
ASX
OECO
Orbital
LSE
50ZY
Int.fin. 46
COIN
ASAETH
Asura World Coin
NYSE
RJF.P.B
Raymond James Fi
EU
IFDNE
FT FDNE INAV
LSE
51FM
Int.fin. 46
KUCN
FOTABTC
Fortuna
LSE
52HO
Sth.e.wtr.11%db
COIN
CSTETH
Cryptosolartech
NYSE
PPT
Putnam Premier Income
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés